Premium
P2‐378: Combination therapy for Alzheimer's disease: Memantine and cholinesterase inhibitors
Author(s) -
Schmidtke Klaus
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.1088
Subject(s) - memantine , donepezil , placebo , medicine , rivastigmine , pharmacology , galantamine , cholinesterase , clinical global impression , psychology , dementia , disease , pathology , alternative medicine
ations and disease duration did not correlate with likelihood of detecting epileptiform activity. Conclusions: In this pilot investigation, people with MCI and early-onset AD had subclinical epileptiform abnormalities that were not observed in age-matched controls. This study is expanding enrollment to identify endophenotypes of people with early cognitive impairment who have epileptiform activity and could possibly benefit from FDA-approved antiepileptic medications.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom